82%, 64%, 44%, and 35%, respectively. The median survival time was 13.8 years. At 5, 10, 15, and 20 years, 55%, 44%, 40%, and 37% of patients, respectively, were relapse-free. Only five of 47 patients who reached 10 years without relapse subsequently developed recurrence. Survival and freedom from relapse (FFR) were significantly worse for older patients. Relapse rates were lower following treatment on both sides of the diaphragm or staging laparotomy. Univariate analysis showed that youth and staging laparotomy were associated with significantly better survival and that FFR was better following treatment on both sides of the diaphragm or laparotomy.
Conclusion 
PATIENTS AND METHODS
Between 1961 and 1994, 177 patients with stage I or II NHL with follicular small cleaved-cell or follicular mixed small cleaved-cell and large-cell histology received radiotherapy with curative intent at Stanford University Hospital. In all cases, slides were reviewed within the institution and initially classified according to either the Rappaport classification 7 or the International Working Formulation. 8 Histology, which was originally reported using the Rappaport classification, was translated into Working Formulation nomenclature (nodular poorly differentated lymphocytic = follicular small cleaved-cell and nodular mixed = follicular mixed). Patients were staged using the Ann Arbor criteria' and generally underwent bone marrow biopsy and bipedal lymphangiography. Staging laparotomy was performed in 45 patients, principally in the era before computed tomographic (CT) scanning became available and when the value of staging laparotomy in the management of NHLs was being studied. All 177 patients received radiotherapy initially. In nine cases, chemotherapy was administered subsequently as adjuvant treatment. Most of these patients received six cycles of cyclophosphamide, vincristine, procarbazine, and predmsone (C-MOPP). Radiation was generally administered using photons from a 6-MV linear accelerator. Several distinct radiation techniques were used during different time periods. Patients were treated with either involved-field radiotherapy, extended-field radiotherapy, or total lymphoid irradiation (TLI). The treatment volume for involved-field radiotherapy encompassed the known tumor volume with a margin and often included one or more adjacent uninvolved lymph node groups. Supradi-aphragmatic extended-field radiotherapy consisted of a mantle field, with or without Waldeyer's fields. Subdiaphragmatic extended-field radiotherapy included an inverted Y with a splenic or splenic pedicle field or whole abdominal/pelvic radiotherapy depending on tumor distribution. TLI comprised both supradiaphragmatic and subdiaphragmatic extended fields as described earlier. In a number of these cases, pelvic nodes were not treated (subtotal nodal lymphoid irradiation [STLI] ). To facilitate analysis of the effect of treatment volume, patients were divided into two groups: those who received treatment to one side of the diaphragm (involved field or extended field) and those who received treatment to both sides of the diaphragm (TLI or STLI). Total radiation doses of 35 Gy to 50 Gy were given m 1.5-to 2.5-Gy fractions four or five times per week. Most patients received < 44 Gy. Higher doses were administered to small volumes as boosts to regions of gross disease in the penod before good dose-response data were available for low-grade lymphomas.
Careful long-term follow-up evaluation was maintained. Regular evaluations included interim history, physical examination, complete blood cell counts, chemistry surveys, chest x-ray, and abdominal xray (for patients who had undergone lymphography). Information on patients unable to attend the clinic at Stanford was obtained by contact with the patient or with the physician responsible for followup evaluation. Patient data were entered onto a data base created on a VAX mainframe computer (Digital Equipment Corporation, Maynard, MA).
Survival and FFR were calculated using the Kaplan-Meier method.i' The generalized Wicoxon test of Gehan" was used to analyze differences in survival or FFR between groups of patients, and prognostic factors were studied using the multivariate technique of Cox. '2 Survival of patients in the study group was compared with survival in a control group. Individual patients were matched by age and sex with controls selected at random from a data base that contained survival data for a large population of California residents. This was intended to give a visual impression of how survival for the study group compared with a normal population. Because the treated population was not drawn from all regions of California with equal probability, direct statistical comparisons were not made.
RESULTS

Patient Demographics
Characteristics of study patients are listed in Table 1 . There were 73 (41%) stage I patients and 104 (59%) stage II. Ninety-seven patients were men (55%) and 83 were women (45%). The median age for men was 52 years (range, 22 to 83) and the median age for women was 53 years (range, 31 to 82, with the exception of one outlying Table 2 . Five patients (3%) had B symptoms.
FFR and Survival
The median follow-up duration was 7.7 years. Figure  1 shows the Kaplan-Meier plots for FFR and survival for all 177 patients. The median survival time was 13.8 years. The percentages of patients alive at 5, 10, 15, and 20 years were 82%, 64%, 44%, and 35%, respectively, for stage I and II combined. There was no difference in survival between stage I and stage II patients (10-year survival rate, 63% v 65%). The FFR percentages at 5, 10, 15, and 20 years were 55%, 44%, 40%, and 37%, respectively, for stages I and II combined. There was no significant difference in FFR between stage I and stage II (10-year FFR rate, 42% v 45%). After 10 years, only two of 19 stage I patients at risk and three of 27 stage II patients at risk had relapsed. The latest relapse occurred in a stage II patient almost 22 years after radiotherapy.
Patients aged -40 years had significantly longer survival times compared with older patients (P = .05), although, the FFR rate was the same in the two groups (data not shown). A much greater effect of age was seen when survival of patients aged greater than 60 years was studied. In addition to survival curves for patients aged greater than and less than 60 years of age, Fig 2 shows survival curves for randomly selected age-and sexmatched controls. The difference in survival between pa- 
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tients aged greater than and less than 60 years is highly statistically significant (P = .0001), but is strongly influenced by the high incidence of intercurrent deaths in the ageing population. The survival curve for controls aged greater than 60 years illustrates the rapidly rising death rate from other causes expected in this age group. However, for both age groups, the presence of lymphoma had a negative impact on survival. Analysis of FFR demonstrated a significantly worse outcome for patients older than 60 years (median, 4.3 years for patients > 60 v 9.0 years for patients < 60, P = .038) (Fig 3) . The effect of radiation treatment volume on FFR is shown in Fig 4A. Treatment on both sides of the diaphragm was associated with a significantly lower relapse rate compared with treatment on one side only (P = .001). At 10 years, only 36% of patients treated on one side of the diaphragm were relapse-free, compared with 67% of patients treated on both sides. Despite this, survival was similar for the two groups (Fig 4B) . Duration of survival after first relapse was not significantly different for patients who had treatment to both sides of the diaphragm compared with patients treated on one side only; median survival times were 6.5 years and 
5.1 years, respectively. Of 21 deaths in patients who received treatment on both sides of the diaphragm, 14 (66.6%) were due to causes other than lymphoma. For extended-or involved-field patients, only 18 (33%) of 60 deaths were due to nonlymphoma causes. No single consistent cause was identified for the relatively high nonlymphoma mortality rate in those patients who had received TLI or STLI. Solid tumors were diagnosed in seven of 41 patients (17%) who received treatment to both sides of the diaphragm, and resulted in death in five of these patients (12%). In patients treated on one side of the diaphragm only, nine of 136 (6.7%) developed solid tumors, of which seven (5.1%) were fatal. A variety of common solid tumor types were encountered (Table 3 ). In addition, there was one case each of acute leukemia and mycosis fungoides, both of which occurred in patients treated only on one side of the diaphragm. The 45 patients who underwent staging laparotomies had a significantly better FFR rate than clinically staged patients (Fig 5 [P = .004] ), but the trend toward improved survival was not statistically significant (data not shown [P = .065]). When the 17 patients with stage I disease who underwent laparotomy were compared with the 56 clinical stage I patients, both FFR (P = .008) and survival (P = .016) were significantly better for the patients who underwent laparotomy (data not shown), but no difference for either FFR or survival was seen in stage II patients. The median age of stage I laparotomy patients was significantly lower than that of clinically staged patients (52 years v 55 years).
The presence of extranodal disease had no significant effect on survival or FFR, either overall or within each stage. There was no difference in survival or FFR between men and women. Only five patients had 'B' symptoms and all of these were stage II. Three of these patients relapsed within 5 years and the other two have not yet reached 5-year follow-up status.
Analysis of Prognostic Factors
The effects of various prognostic variables on FFR and survival were studied using univariate and multivariate analysis. Results are listed in Table 4 . For survival, increasing age emerged as, by far, the most important variable, but staging laparotomy also had a significant effect. Sex, stage, histology, presence of an extranodal site, and treatment on both sides of the diaphragm did not significantly influence survival when considered as separate variables. For FFR, the individual variables that had the greatest influence were treatment on both sides of the diaphragm and staging laparotomy. The effect of age on FFR was not statistically significant (P = .097).
When multivariate analysis was used to correct for the powerful influence of age on survival, extranodal involvement, stage II disease, follicular mixed histology, female sex, and treatment on only one side of the diaphragm had statistically significant adverse effects on survival, although, for most of these factors, the apparent increase in relative risk was small. When FFR was analyzed using the same method, correcting for the influence of both laparotomy and treatment on both sides of the diaphragm, age greater than 60 years, extranodal involvement, stage II disease, female sex, and follicular mixed histology were shown to have statistically significant adverse effects on 
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outcome, although only in the case of age was the relative risk substantial.
Outcome Following First Relapse
Relapse occurred in 91 patients (51%). In 19 cases, repeat biopsy after first or subsequent relapse showed evolution to intermediate-or high-grade lymphoma. Treatment following first relapse varied with extent of disease and patient age and performance status. Management strategies included initial observation with treatment only on symptomatic disease progression, further radiotherapy, and chemotherapy with single or multiple cytotoxic drugs. The median survival time after first relapse was 5 years. Ten years after relapse, the actuarial survival rate was 32%. A detailed analysis of relapsed patients is currently in preparation.
DISCUSSION
This analysis was confined to follicular lymphomas with small cleaved-cell or mixed small cleaved-cell and largecell morphology, because the natural history and response to treatment is similar for these favorable histologies. Other "tTotal of 9 tumors in 133 patients treated (6.8%), with 7 fatalities (5.2%).
published series" 3 '14 and earlier analyses of the Stanford expe- reported here are broadly similar to those reported by other investigators. [13] [14] [15] [16] [17] [18] Although 56% of patients in this series relapsed within 10 years of treatment, many remained in remission for the duration of their lives and died of unrelated causes. A patient who has survived for 10 or more years without relapse may reasonably ask "Am I cured?" There are few large series of patients with sufficiently long followup to address this question. Although the number of patients who have been monitored for more than 20 years is still relatively small, this series includes patients who participated in some of the earliest systematic clinical trials of modem radiotherapy in NHL and some longterm follow-up information is available. This information may be useful in counseling long-term survivors.
At the time of this analysis, 49 patients had been monitored for 10 years without relapse and 11 patients had reached 20 years without treatment failure. Only four relapses occurred between 10 and 20 years after treatment and only one relapse occurred later than 20 years. The longest survivor remained relapse-free 31 years after treatment. The latest relapse occurred almost 22 years after treatment. Although one cannot draw firm conclusions, our data suggest that a plateau is approached approximately 10 years after primary treatment, beyond which relapses occur only infrequently. When a patient asks if he or she is cured 10 years after treatment, a reasonable reply may be "relapse of your disease is now very unlikely, but the risk will probably never reduce to zero."
As in previous studies, 3 ' 13'14,1 9 analysis of the influence of various prognostic factors confirmed the negative im- pact of increasing age on survival. Patients older than 40 years and particularly those older than 60 years had significantly worse prospects for survival than younger patients. Although death rates from intercurrent illness normally increase markedly after the age of 60 years, older patients in this series had a much higher death rate than an age-and sex-matched control population. Relapse rates were also significantly higher for patients aged more than 60 years. This may indicate that the disease is intrinsically more aggressive in these cases, that it is less responsive to treatment, that occult spread may be more common at the time of diagnosis, or even that host defenses against occult disease are impaired in older patients. Alternatively, staging and treatment may have been less intensive.
Administration of radiotherapy to nodal areas on both sides of the diaphragm was associated with a significant increase in FFR compared with more localized treatment, but did not translate into a clear survival benefit. These findings are consistent with those reported by other investigators.3.15 " In this study, the death rate from lymphoma was considerably lower in patients who received TLI or STLI, but their overall survival was similar to that of patients treated with involved or extended fields. This must be explained by a higher incidence of death due to other causes in patients treated on both sides of the diaphragm, but no consistent alternative cause of mortality was observed in these cases. Nevertheless, the incidence of solid tumors was considerably greater in patients treated on both sides of the diaphragm (17% v 6.7%) and the mortality rate from solid tumors was also higher (12% v 5.1%), accounting for at least a part of the observed increase in nonlymphoma deaths. Because there is no clear survival benefit from treatment on both sides of the diaphragm, patients treated at Stanford in recent years have received radiotherapy to involved or extended fields only.
The 45 patients in this series who underwent staging laparotomies constitute one of the few substantial cohorts of pathologically confirmed, early-stage, low-grade follicular lymphoma treated by radiotherapy. In approximately one third of patients with clinical stage I or II disease who had staging laparotomies at Stanford, lymphoma was found in the spleen, liver, or other abdominal or pelvic sites, which resulted in upstaging to pathological stage III or IV.
The observation of sporadic recurrence, even decades after primary treatment, is difficult to explain on the basis of conventional tumor growth kinetic models. 22 It may be that in some cases, a second follicular lymphoma has arisen de novo in a genetically predisposed individual. Alternatively, recurrence may be due to renewed proliferation of a lymphoma cell population that had remained in resting phase for many years. Recent studies of the bcl-2 proto-oncogene, which is deregulated and overexpressed in most follicular lymphomas, suggest that patients may live for many years without relapse despite the presence of circulating cells that bear the t(14; 18) translocation,23,24 which leads to abnormal bcl-2 expression. 
